Optimized Lipid Nanoparticles for Pioglitazone Delivery: Molecular Docking Insights and In Vivo Efficacy in Nonalcoholic Steatohepatitis
Nano LIFE · 2027-02 · 17 (01)
DOI: 10.1142/s1793984426500030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nano LIFE, online erschienen am 31.03.2026. Verfasst von Shimul Halder und 7 weiteren Autor:innen. Die Arbeit nennt 45 Literaturangaben. Gefördert von: University Grants Commission of Bangladesh.
Abstract (Originalsprache)
Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with limited therapeutic options, where pioglitazone (PGZ), a PPAR-[Formula: see text] agonist, has shown promise but suffers from poor solubility and systemic side effects. In this study, we developed and optimized lipid nanoparticles (LNP-PGZ) to enhance the targeted delivery and therapeutic efficacy of PGZ for the treatment of NASH. The formulation was designed to improve solubility and stability, and was characterized through detailed physicochemical analyses, including particle size distribution and in vitro dissolution studies. The optimized LNP-PGZ exhibited a particle size of 56.7 nm, a PDI of 0.113, an EE% of 85% and a DL% of 8.5%. Moreover, the optimized LNP-PGZ exhibited a controlled drug-release profile compared with free PGZ, suggesting improved therapeutic potential. Molecular docking studies further supported the formulation’s effectiveness by demonstrating strong binding affinity of PGZ for key NASH-related targets, including PPAR-[Formula: see text] and STK25, highlighting its potential to modulate metabolic and inflammatory pathways. In vivo efficacy was evaluated in a rat model of NASH induced by a high-fat diet (HFD). Furthermore, LNP-PGZ significantly reduced liver damage in rats with HFD-induced hepatic injury, with 91.7% ([Formula: see text] < 0.001) reduction in ALT and 86.8% ([Formula: see text] < 0.001) in AST (Group IV) compared to the disease control (Group II). These findings collectively suggest that LNP-PGZ not only enhances its solubility and bioavailability but also amplifies its therapeutic benefits in NASH, potentially reducing off-target effects. This integrated approach, combining molecular modelling and in vivo validation, offers a promising platform for advancing safer, more effective treatments for liver diseases, such as NASH.
Förderung
- University Grants Commission of Bangladesh
Zitieren
APA
Halder, S., Hossain, T., Nasrin, N., Reza, R., Samdani, M. N., Shill, M. C., Chowdhury, J. A., & Reza, M. S. (2027). Optimized Lipid Nanoparticles for Pioglitazone Delivery: Molecular Docking Insights and In Vivo Efficacy in Nonalcoholic Steatohepatitis. Nano LIFE, 17(01). https://doi.org/10.1142/s1793984426500030
Vancouver
Halder S, Hossain T, Nasrin N, Reza R, Samdani MN, Shill MC, et al. Optimized Lipid Nanoparticles for Pioglitazone Delivery: Molecular Docking Insights and In Vivo Efficacy in Nonalcoholic Steatohepatitis. Nano LIFE. 2027;17(01). doi:10.1142/s1793984426500030
BibTeX
@article{Halder2027,
author = {Halder, Shimul and Hossain, Tanveer and Nasrin, Najibah and Reza, Rumman and Samdani, Md. Nazmus and Shill, Manik Chandra and Chowdhury, Jakir Ahmed and Reza, Md. Selim},
title = {Optimized Lipid Nanoparticles for Pioglitazone Delivery: Molecular Docking Insights and In Vivo Efficacy in Nonalcoholic Steatohepatitis},
journal = {Nano LIFE},
year = {2027},
volume = {17},
number = {01},
doi = {10.1142/s1793984426500030}
}
EUVIMED